Nigericin-mediated liposome loading of topotecan: Is nigericin a potential drug release regulator?

International Journal of Pharmaceutics

Volumn 399, Issue 1-2, 2010, Pages 31-36

  Cui, JingXia ^a   Li, ChunLei ^b,c   Wang, CaiXia ^b,c   Li, YanHui ^b,c   Zhang, Lan ^b,c   Zhang, Li ^b,c   Xiu, Xian ^b,c   Li, YongFeng ^b,c   Wei, Na ^b,c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co Ltd   (China)

^c Hebei Pharmaceutical Engineering and Technology Research Center   (China)

Author keywords

Active loading; Drug release; Efficacy; Liposomes; Nigericin; Pharmacokinetics; Topotecan; Toxicity

Indexed keywords

CARBOXYLIC ACID; LACTONE; LIPOSOME; NIGERICIN; TOPOTECAN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; DEATH; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG RETENTION; DRUG SAFETY; ENCAPSULATION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PH; PLASMA; PRIORITY JOURNAL; TOXICITY; TUMOR MODEL;

ANIMALS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; LEUKEMIA L1210; MALE; MICE; MICE, INBRED DBA; NIGERICIN; SURVIVAL ANALYSIS; TIME FACTORS; TOPOISOMERASE I INHIBITORS; TOPOTECAN; UNILAMELLAR LIPOSOMES;

EID: 77956884234     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.050     Document Type: Article

References (33)

1. Abraham S.A., Edwards K., Karlsson G., MacIntosh S., Mayer L.D., McKenzie C., Bally M.B. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim. Biophys. Acta 2002, 1565:41-54.
2. Abraham S.A., McKenzie C., Masin D., Ng R., Harasym T.O., Mayer L.D., Bally M.B. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin. Cancer Res. 2004, 10:728-738.
3. Boman N.L., Mayer L.D., Cullis P.R. Optimization of the retention properties of vincristine in liposomal systems. Biochim. Biophys. Acta 1993, 1152:253-258.
4. Burke T.G., Gao X. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J. Pharm. Sci. 1994, 83:967-969.
5. Chakrabarti A.C., Veiro J.A., Wong N.S., Wheeler J.J., Cullis P.R. Generation and characterization of iron- and barium-loaded liposomes. Biochim. Biophys. Acta 1992, 1108:233-239.
6. Chiu G.N., Abraham S.A., Ickenstein L.M., Ng R., Karlsson G., Edwards K., Wasan E.K., Bally M.B. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J. Control. Release 2005, 104:271-288.
7. Cui J., Li C., Guo W., Li Y., Wang C., Zhang L., Zhang L., Hao Y., Wang Y. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?. J. Control. Release 2007, 118:204-215.
8. Cullis P.R., Bally M.B., Madden T.D., Mayer L.D., Hope M.J. pH gradients and membrane transport in liposomal systems. Trends Biotechnol. 1991, 9:268-272.
9. Cullis P.R., Hope M.J., Bally M.B., Madden T.D., Mayer L.D., Fenske D.B. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta 1997, 1331:187-211.
10. Dennis M.J., Beijnen J.H., Grochow L.B., van Warmerdam L.J. An overview of the clinical pharmacology of topotecan. Semin. Oncol. 1997, 24. S5-12-S15-18.
11. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51:691-743.
12. Drummond D.C., Noble C.O., Guo Z., Hayes M.E., Connolly-Ingram C., Gabriel B.S., Hann B., Liu B., Park J.W., Hong K., Benz C.C., Marks J.D., Kirpotin D.B. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J. Control. Release 2010, 141:13-21.
13. Fenske D.B., Cullis P.R. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol. 2005, 391:7-40.
14. Fenske D.B., Wong K.F., Maurer E., Maurer N., Leenhouts J.M., Boman N., Amankwa L., Cullis P.R. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim. Biophys. Acta 1998, 1414:188-204.
15. Hao Y.L., Deng Y.J., Chen Y., Wang K.Z., Hao A.J., Zhang Y. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan. J. Pharm. Pharmacol. 2005, 57:1279-1287.
16. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1993, 1151:201-215.
17. Herben V.M., ten Bokkel Huinink W.W., Beijnen J.H. Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet. 1996, 31:85-102.
18. Johnston M.J., Semple S.C., Klimuk S.K., Edwards K., Eisenhardt M.L., Leng E.C., Karlsson G., Yanko D., Cullis P.R. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim. Biophys. Acta 2006, 1758:55-64.
19. Jones S.F., Burris H.A. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Pract. 1996, 4:51-53.
20. Lasic D.D., Ceh B., Stuart M.C., Guo L., Frederik P.M., Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim. Biophys. Acta 1995, 1239:145-156.
21. Liu J.J., Hong R.L., Cheng W.F., Hong K., Chang F.H., Tseng Y.L. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. Anticancer Drugs 2002, 13:709-717.
22. Maurer-Spurej E., Wong K.F., Maurer N., Fenske D.B., Cullis P.R. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. Biochim. Biophys. Acta 1999, 1416:1-10.
23. Mayer L.D., Bally M.B., Cullis P.R. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta 1986, 857:123-126.
24. Messerer C.L., Ramsay E.C., Waterhouse D., Ng R., Simms E.M., Harasym N., Tardi P., Mayer L.D., Bally M.B. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin. Cancer Res. 2004, 10:6638-6649.
25. Redelmeier T.E., Mayer L.D., Wong K.F., Bally M.B., Cullis P.R. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys. J. 1989, 56:385-393.
26. Semple S.C., Leone R., Wang J., Leng E.C., Klimuk S.K., Eisenhardt M.L., Yuan Z.N., Edwards K., Maurer N., Hope M.J., Cullis P.R., Ahkong Q.F. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J. Pharm. Sci. 2005, 94:1024-1038.
27. Subramanian D., Muller M.T. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. Oncol. Res. 1995, 7:461-469.
28. Taggar A.S., Alnajim J., Anantha M., Thomas A., Webb M., Ramsay E., Bally M.B. Copper-topotecan complexation mediates drug accumulation into liposomes. J. Control. Release 2006, 114:78-88.
29. Tardi P., Choice E., Masin D., Redelmeier T., Bally M., Madden T.D. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 2000, 60:3389-3393.
30. Waterhouse D.N., Madden T.D., Cullis P.R., Bally M.B., Mayer L.D., Webb M.S. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol. 2005, 391:40-57.
31. 2+ into large unilamellar vesicles in response to transmembrane pH gradients. Mol. Membr. Biol. 1994, 11:151-157.
32. Zhigaltsev I.V., Maurer N., Akhong Q.F., Leone R., Leng E., Wang J., Semple S.C., Cullis P.R. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J. Control. Release 2005, 104:103-111.
33. Zhigaltsev I.V., Maurer N., Edwards K., Karlsson G., Cullis P.R. Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J. Control. Release 2006, 110:378-386.